CURX news & sentiment — Curanex Pharmaceuticals Inc

MAR 31·TradingViewLow

CURX: IPO proceeds fund R&D for Phyto-N; no revenue, $4.2M net loss, and internal control weaknesses

Curanex Pharmaceuticals Inc. (CURX) completed its IPO in 2025, raising $17.25 million, but reported no revenue and a net loss of $4.2 million due to increased R&D and general & administrative expenses. Its flagship product, Phyto-N, is in preclinical development, with an IND submission for ulcerative colitis planned for late 2026. The company faces ongoing material weaknesses in internal controls and risks related to its Nasdaq listing.

MAR 12·Investing.com Australia

Curanex adds two advisors to scientific board ahead of IND filing

Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise as it prepares for an Investigational New Drug (IND) filing for its lead candidate, Phyto-N. The company, which focuses on botanical drugs for inflammatory diseases, aims for IND submission and Phase I clinical trials in Q4 2026. Despite recent stock declines, Curanex (NASDAQ:CURX) shows financial stability with strong liquidity and more cash than debt.

FEB 25·The Manila Times

Curanex Provides Operational Update on Key Regulatory Milestones

Curanex Pharmaceuticals Inc. announced the successful completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This milestone is crucial for its planned Investigational New Drug (IND) submission for ulcerative colitis, targeted for Q4 2026. The company is now advancing GLP toxicology and pharmacokinetic studies to support the regulatory submission.

$CURX

CURX: IPO proceeds fund R&D for Phyto-N; no revenue, $4.2M net loss, and internal control weaknesses

Curanex adds two advisors to scientific board ahead of IND filing

Curanex Provides Operational Update on Key Regulatory Milestones

News on $CURX